PF-04449613 is a phosphodiesterase 9A (PDE9A) inhibitor (IC50= 22 nM).1It is selective for PDE9A over PDE1C (IC50= >1,000 nM), as well as over a variety of other PDEs, inhibiting PDE2-8, -10, and -11 activity by less than 30% in a panel of enzymes, ion channels, and transporters at 1 μM but does inhibit the human dopamine transporter (DAT; Ki= 293 nM). PF-04449613 (0.1-100 mg/kg, s.c.) increases cerebrospinal fluid (CSF) levels of cyclic GMP (cGMP) in rats. Subcutaneous administration of PF-04449613 (10 mg/kg) increases the rate of dendritic spine formation and elimination in mouse primary motor cortex pyramidal neuronsin vivo.2It increases the average running speed of mice in an accelerating rotarod task, indicating improved motor learning, at the same dose. 1.Claffey, M.M., Helal, C.J., Verhoest, P.R., et al.Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitorsJ. Med. Chem.55(21)9055-90

PDE7 inhibitor S14 is a cell-permeable PDE7 inhibitor that acts by targeting the cyclic adenosine monophosphate (cAMP)/cAMP-response element-binding protein (CREB) pathway.

PF-8380 hydrochloride 是一种有效的autotaxin 抑制剂，体外酶实验和人类全血细胞实验中，IC50分别为 2.8 nM 和 101 nM。

Indantadol HCl (CHF-3381) 是一种 NMDA 拮抗剂和非选择性 MAO 抑制剂。

Lazabemide hydrochloride (N-(2-Aminoethyl)-5-chlor-2-pyridincarbox) 是一种单胺氧化酶 B 的选择性的可逆抑制剂，但对 MAO-A 活性较低。它在高浓度时，具有抑制单胺摄取的作用，抑制去甲肾上腺素、血清素和多巴胺摄取。它可用于研究帕金森和阿尔茨海默病。

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone 是弱MAO-A 抑制剂，IC50=183 μM，对 MAO-B 无作用。